The Effects Of AQX-1125, A Selective Oral SHIP1 Activator, On Lipopolysaccharide-Induced Cellular And Biochemical Changes In Sputum From Healthy Volunteers

Trial Profile

The Effects Of AQX-1125, A Selective Oral SHIP1 Activator, On Lipopolysaccharide-Induced Cellular And Biochemical Changes In Sputum From Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2013

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Allergic asthma; Immunological disorders
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 30 May 2013 New trial record
    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top